China NT Pharma Group Company Limited released its unaudited results for the six months ended 30 June 2026, showing a sharp revenue rebound but only a marginal improvement in bottom-line losses and continued balance-sheet stress.

Revenue and profitability • Turnover jumped 97.3% year on year to RMB 23.67 million, driven by the addition of a RMB 8.03 million contribution from the newly launched medical-equipment segment and solid growth in agency services (+32.9%) and healthcare services (+27.9%). • Gross profit contracted 30.6% to RMB 6.95 million as service costs expanded more than eight-fold to RMB 16.72 million, compressing the gross margin to 29.4% (1H25: 83.5%). • Segment results: agency services generated RMB 3.02 million profit, medical equipment RMB 2.55 million, while healthcare services recorded a RMB 0.59 million loss; however, finance costs of RMB 12.84 million and RMB 6.57 million of unallocated G&A drove a pre-tax loss of RMB 16.54 million (1H25: RMB 16.91 million loss). • Net loss attributable to shareholders was RMB 18.43 million, versus RMB 16.91 million a year earlier. Basic and diluted loss per share narrowed to RMB 2.24 cents from RMB 3.03 cents on a higher share count (821.49 million vs 558.68 million).

Balance sheet and liquidity • Net liabilities improved to RMB 51.30 million from RMB 273.83 million at end-2025, reflecting share issuances and asset additions. • Net current liabilities remained substantial at RMB 616.86 million, while all borrowings of RMB 332.32 million fall due within 12 months. Cash and bank balances stood at just RMB 11.91 million. • The group also carries contingent liabilities of RMB 133.01 million under financial guarantee contracts linked to former subsidiaries. • Management is negotiating loan extensions and has signed subscription agreements to issue 847.57 million new shares at HKD 0.365 each to convert part of its debt to equity, subject to shareholder and regulatory approvals.

Strategic moves • NT Pharma is repositioning as a “testing-treatment-rehabilitation” bone-health ecosystem provider. • In March 2026 the company issued 274.75 million new shares to acquire a 58.11% stake in Zhejiang Kangyuan Medical Equipment, adding RMB 191.84 million of intangible assets and RMB 88.58 million of goodwill. • The new medical-equipment business—mainly AI-driven bone-density testing robots—contributed 34% of group revenue in its first reported half-year.

Outlook and capital management Management targets further commercialization of bone-health products and services, continuation of debt-restructuring talks, pursuit of new financing and strategic investors, and expansion of AI healthcare assets. The company did not declare an interim dividend.

Auditor review and governance The interim results were reviewed by the Audit Committee. The board states that the group remains a going concern based on planned financing and operational measures, though it acknowledges “material uncertainties” tied to debt repayment and guarantee obligations.